Vaginal suppository vaccine for urogenital infections

A suppository-based vaccine delivery system for enhancing resistance to urinary tract infections in humans, said suppository comprising:

• (a) a vaccine comprised of inactivated bacteria which originate from cultures of 8 to 14 uropathogenic bacteria strains isolated from the urine of persons suffering from a urinary tract infection of the species:
• Escherichia coli, Klebsiella pneumnoniae, Proteus mirabilis, Proteus morganii, and Streptococcus faecalis, and are present in an amount of about 50 million to about 5 billion germs of each strain per suppository, wherein one-half to three-quarters of the strains used belong to Escherichia coli species;
• and
• (b) polyethylene glycol suppository base,
• wherein the suppository is adapted to be inserted vaginally so as to allow the suppository to be in contact with vaginal mucous membrane to facilitate transfer of suppository material therethrough.

A suppository-based vaccine delivery system for enhancing resistance to urinary tract infections in humans, said suppository comprising:

• (a) a vaccine comprised of inactivated bacteria which originate from cultures of 8 to 14 uropathogenic bacteria strains isolated from the urine of persons suffering from a urinary tract infection of the species:
• Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus morganii, and Streptococcus faecalis, and are present in an amount of about 50 million to about 5 billion germs of each strain per suppository, wherein one-half to three-quarters of the strains used belong to Escherichia coli species, wherein the inactive bacteria originate from 6 strains of the species Escherichia coli and 1 strain each of Klebsiella pneumoniae, Proteus mirabilis, Proteus morganii, and Streptococcus faecalis, and wherein the inactive bacteria are present in the total amount of about 1.times.10.sup.9 to about 1.times.10.sup.10 germs;
• and
• (b) polyethylene glycol suppository base,
• wherein the polyethylene glycol suppository base is comprised of about 98% by weight polyethylene glycol and about 2% by weight polysorbate, wherein the polyethylene glycol has an average molecular weight of about 3000 to about 5000, and wherein the polyethylene glycol suppository base comprises from about 80% to about 95% by weight of the suppository;
• wherein the suppository is adapted to be inserted vaginally so as to allow the suppository to be in contact with vaginal mucous membrane to facilitate transfer of suppository material therethrough.

A method for enhancing resistance to urogenital disease in humans, said method comprising the steps of:

• (a) inserting a suppository-based vaccine delivery system into a bodily orifice of a human, wherein said suppository is comprised of a vaccine comprised of inactivated bacteria which originate from cultures of 8 to 14 uropathogenic bacteria strains of the species:
• Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus inorganii, and Streptococcus faecalis, and are present in an amount of about 50 million to about 5 billion germs of each strain per suppository, wherein one-half to three-quarters of the strains used belong to Escherichia coli species;
• and polyethylene glycol suppository base;
• and
• (b) contacting the suppository with tissue of the bodily orifice to facilitate transfer of suppository material therethrough and induce an immune response in the human.

A method of enhancing resistance to urinary tract infections in humans, said method comprising the steps of:

• (a) inserting a suppository-based vaccine delivery system into a vagina of a human, wherein said suppository is comprised of a vaccine comprised of inactivated bacteria which originate from cultures of 8 to 14 uropathogenic bacteria strains of the species:
• Escherichia coli, Klebsiella pineumoniae, Proteus mirabilis, Proteus morganii, and Streptococcus faecalis, and are present in an amount of about 50 million to about 5 billion germs of each strain per suppository, wherein one-half to three-quarters of the strains used belong to Escherichia coli species;
• and polyethylene glycol suppository base;
• and
• (b) contacting the suppository with vaginal mucous membrane to facilitate transfer of suppository material therethrough and induce an immune response in the human.